Performance-Driven Site Network Exceeds Published Industry Benchmarks

Iterative Health, a healthcare technology and services company powering the acceleration of clinical research, today announced the publication of scientific research at the 21st Congress of European Crohn’s and Colitis Organisation (ECCO), taking place Feb. 18–21, 2026, in Stockholm, Sweden. The abstract highlights performance metrics across Iterative Health’s global research network compared to published industry benchmarks, demonstrating the impact of a site-centric partnership model in improving trial execution and bringing novel therapies to patients faster.

“The research investigated an innovative approach to longstanding challenges in clinical research related to trial delays and lagging enrollment rates across sites,” said Laurent Peyrin-Biroulet, MD, PhD, lead study author and professor of gastroenterology. “With per-site randomization rates falling by more than 70% over the last decade in ulcerative colitis and Crohn’s disease, the consistency and scale of performance observed by the Iterative Health site network points to a more sustainable way to drive the development of novel therapies for patients.”

The study, titled “Accelerating enrollment in phase 2 and 3 inflammatory bowel disease trials through an innovative site network,” evaluated performance across several ulcerative colitis and Crohn’s disease randomized controlled trials conducted across the United States and Europe. As part of Iterative Health’s performance-driven network, sites are empowered with operational infrastructure, standardized processes, study-specific training, and AI-powered technology designed to drive trial success and sustainability.

“From a U.S. site perspective, the trial performance reflected in this data is particularly meaningful,” said J. Casey Chapman, MD, study author and Chief Medical Officer of GI Alliance. “When a purpose-built clinical research infrastructure focuses on high-performing, sustainable, community-based research sites, it becomes possible to set a higher standard for enrollment and speed. Trials can move forward more efficiently, expanding access to treatment options and ultimately advancing patient care.”

Across U.S. and European sites within Iterative Health’s network, sites enrolled patients at an unprecedented average rate of 0.34 per month, approximately 3.4 times higher than published industry benchmarks. Activation timelines were also shorter, with a median of 74 days from selection to activation compared to 120–171 days in published industry benchmarks, demonstrating a 3-month time savings opportunity. These results show that consistent processes and practical tools can help trials begin sooner and enroll patients more efficiently without compromising quality.

“This publication marks the first time Iterative Health has reported aggregated performance metrics and reflects our promise of data-driven and impactful innovation,” said Dana Feuchtbaum, Chief Operating Officer of Iterative Health. “The results demonstrate a business model that is intentionally designed to accelerate clinical research, paving the way to expand across GI, hepatology, and additional therapeutic areas.”

Consistent performance above industry benchmarks across the U.S. and Europe, Phase II and III trials, and two complex disease indications highlight Iterative Health’s scalable approach and the growing evidence that site-centric, integrated research operations can improve trial execution and accelerate the development of novel therapies.

About Iterative Health

Iterative Health is a healthcare technology and services company powering the acceleration of clinical research to transform patient outcomes. By combining deep expertise in clinical trials with cutting-edge AI, we empower research teams and study sponsors to expand and expedite access to novel therapeutics for patients in need. The company has headquarters in Cambridge, Massachusetts, and New York, New York. For more information, visit www.iterative.health and follow us on LinkedIn for the latest company updates.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260219060985/en/